Repros discontinues highest dose of Proellex in endometriosis trial
This article was originally published in Scrip
Repros Therapeutics is discontinuing the 50mg dose of its endometriosis candidate, Proellex (CDB-4124), in a Phase II trial, because it lacks therapeutic differentiation from the lower doses of the drug. The 50mg dose was also found to elevate liver enzymes – an indication of toxicity - in a subset of women in the trial who had endometriosis-associated anaemia.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.